Carl Zeiss Meditec AG
XETRA:AFX
Intrinsic Value
Carl Zeiss Meditec AG engages in the development, manufacture and marketing of medical devices. [ Read More ]
The intrinsic value of one
AFX
stock under the Base Case scenario is
105.45
EUR.
Compared to the current market price of 102.4 EUR,
Carl Zeiss Meditec AG
is
Undervalued by 3%.
Carl Zeiss Meditec AG's market capitalization is 9.2B EUR.
AFX stock price is 102.4 EUR.
AFX stock price (102.4 EUR) is 3% less than its Intrinsic Value (105.45 EUR).
AFX stock price (102.4 EUR) is 21% less than its Relative Value (129.88 EUR). Open Relative Valuation
AFX has upside potential of 10% compared to the average analyst price target.
Open Wall St Estimates
AFX's ROIC (Return on Invested Capital) has increased in the last 3 years from 9% to 9%.
AFX's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
AFX has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
AFX's Revenue has been growing by 2% per year for the last 3 years.
AFX's Revenue has grown by 7% over the past 12 months.
AFX's ROE (Return on Equity) has increased in the last 3 years from 11% to 13%.
AFX's ROE (Return on Equity) for the past 12 months is positive and is equal to 13%.
AFX has positive Net Income for the last twelve months.
AFX has negative Free Cash Flow for the last twelve months.
AFX's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
AFX has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
AFX has positive Operating Income for the last twelve months.
AFX has positive Gross Profit for the last twelve months.
AFX has positive Net Debt. This means that the company has more debt (230m EUR) than cash and short-term investments (39m EUR).
AFX's short-term assets (2B EUR) exceed its short-term liabilties (562m EUR).
AFX's long-term assets (3B EUR) exceed its long-term liabilties (873m EUR).
AFX's D/E (Debt to Equity) is very low and is equal to 0.11.
AFX's Altman Z-Score is very high and is equal to 8.29.
AFX earns more than enough operating income (331m EUR) to safely cover interest payments on its debt (634k EUR).
Valuation Backtest
Carl Zeiss Meditec AG
Run backtest to discover the historical profit from buying and selling
AFX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Carl Zeiss Meditec AG
Balance Sheet Decomposition
Carl Zeiss Meditec AG
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 38.8m |
| Receivables | 1.3B |
| Other Current Assets | 575.8m |
| Non-Current Assets | 1.1B |
| Long-Term Investments | 21.5m |
| PP&E | 315.8m |
| Intangibles | 675.3m |
| Other Non-Current Assets | 108.7m |
| Current Liabilities | 561.6m |
| Accounts Payable | 239.8m |
| Accrued Liabilities | 155.2m |
| Other Current Liabilities | 166.6m |
| Non-Current Liabilities | 311.8m |
| Long-Term Debt | 229.9m |
| Other Non-Current Liabilities | 81.9m |
Earnings Waterfall
Carl Zeiss Meditec AG
|
Revenue
|
2.1B
EUR
|
|
Cost of Revenue
|
-893.1m
EUR
|
|
Gross Profit
|
1.2B
EUR
|
|
Operating Expenses
|
-869.5m
EUR
|
|
Operating Income
|
331.4m
EUR
|
|
Other Expenses
|
-54.6m
EUR
|
|
Net Income
|
276.8m
EUR
|
Free Cash Flow Analysis
Carl Zeiss Meditec AG
What is Free Cash Flow?
AFX Profitability Score
Profitability Due Diligence
Carl Zeiss Meditec AG's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Carl Zeiss Meditec AG's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
AFX Solvency Score
Solvency Due Diligence
Carl Zeiss Meditec AG's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
Carl Zeiss Meditec AG's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AFX Price Targets Summary
Carl Zeiss Meditec AG
According to Wall Street analysts, the average 1-year price target for
AFX
is 113.04 EUR
with a low forecast of 76.76 EUR and a high forecast of 157.5 EUR.
Shareholder Return
AFX Price
Carl Zeiss Meditec AG
| Average Annual Return | 17.99% |
| Standard Deviation of Annual Returns | 46.25% |
| Max Drawdown | -62% |
| Market Capitalization | 9.2B EUR |
| Shares Outstanding | 89 440 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Carl Zeiss Meditec AG
Country
Industry
Market Cap
Dividend Yield
Description
Carl Zeiss Meditec AG engages in the development, manufacture and marketing of medical devices. The company is headquartered in Jena, Thueringen and currently employs 3,531 full-time employees. The company went IPO on 2000-03-20. The company offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The firm operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The firm has various production sites in Europe, the United States and Asia.
Contact
IPO
Employees
Officers
The intrinsic value of one
AFX
stock under the Base Case scenario is
105.45
EUR.
Compared to the current market price of 102.4 EUR,
Carl Zeiss Meditec AG
is
Undervalued by 3%.
You don't have any saved screeners yet
